BioSig CEO Kenneth L. Londoner to Present at the Virtual Investor Conference Small and Microcap Showcase
January 27 2021 - 4:30PM
- Company to provide corporate overview and progress on
the rollout of the PURE EP™ System
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the
"Company"), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that it will present at the Virtual
Investor Conference Small and Microcap Showcase on February 4,
2021.
During the presentation, Kenneth L. Londoner, Chairman, and CEO
of BioSig Technologies, Inc. will provide a Company overview that
includes recent updates on the rollout of BioSig’s PURE EP™ System
and other business highlights. To date, more than 470 patient
procedures have been conducted with the PURE EP ™ System by more
than 32 electrophysiologists across seven different clinical sites
in the United States.
Event: Virtual Investor Conference Small and
Microcap ShowcasePresentation
Date: Thursday, February 4,
2021Presentation Time: 11:30 AM
Eastern
To register, Click here.
About Virtual Investor Conferences®Virtual
Investor Conferences (VIC) is the leading proprietary investor
conference series that provides an interactive forum for publicly
traded companies to meet and present directly with investors.
A real-time solution for investor engagement, Virtual Investor
Conferences is part of OTC Market Group's suite of investor
relations services specifically designed for more efficient
Investor Access. Replicating the look and feel of on-site investor
conferences, Virtual Investor Conferences combine leading-edge
conferencing and investor communications capabilities with a
comprehensive global investor audience network.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP (tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024